Clinical Trial

Clinical Study of Anti-CD19/BCMA Universal Chimeric Antigen Receptor T Cells (UCAR-T) in the Treatment of Refractory Idiopathic Membranous Nephropathy (IMN)

Name: Clinical Study of Anti-CD19/BCMA Universal Chimeric Antigen Receptor T Cells (UCAR-T) in the Treatment of Refractory Idiopathic Membranous Nephropathy (IMN) — clinical trial record (NCT07423572)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Early Phase 1

View on ClinicalTrials.gov →

Summary

A single arm, open-label pilot study is designed to determine the safety and effectiveness of anti-CD19/BCMA Universal Chimeric Antigen Receptor T Cells (UCAR-T) in the Treatment of Refractory Idiopathic Membranous Nephropathy (IMN)

Trial Details

NCT Number	NCT07423572
Lead Sponsor	The First Affiliated Hospital of Zhejiang Chinese Medical University
Conditions	Refractory Idiopathic Membranous Nephropathy
Enrollment	18 participants
Start Date	2026-02-28
Primary Completion	2028-02-28 (estimated)
Study Completion	2029-09-28 (estimated)
Updated on ClinicalTrials.gov	2026-02-20